Medistim celebrate a long-standing relationship with the Japanese cardiac surgery community

02 Dec 2022 08:30 CET

(Oslo, 2end December 2022) Medistim ASA (OSE: MEDI) is a niche market leader
within ultrasound technology with headquarters in Oslo, Norway. Medistim
develops and commercializes medical equipment for use within cardiac, vascular
and transplant surgery. Yesterday, the Counselor Otto Malmgren at the Norwegian
Embassy in Tokyo, gave opening remarks to Medistim’s symposium “The necessity of
quality assessment in CABG” held at the 8th International Coronary Congress in
Tokyo. “This is very much a story of a perfect fit between Norwegian technology
and Japanese quality standards. Medistim technology has been able to meet
expectations of the quality driven Japanese market. There are few arenas in our
societies where precision and reliable tools are as crucial as to the best
outcome for the patients as in complex open-heart surgery,“ says Otto Malmgren.

The symposium is moderated by Dr. Hirokuni Arai, Professor Emeritus of Tokyo
Medical and Dental University and President of Hokushin General Hospital in
Nagano Japan. He is currently Society President of the Japanese Association for
Coronary Artery Surgery (JACAS) and hosting the International Coronary Congress
(ICC) 2022 in Tokyo.

“Medistim has a long history of working together with, and helping to connect,
world leading surgeons to share clinical best practices, and our ongoing support
to the International Coronary Congress is an excellent example,” says Medistim
President and CEO, Kari E. Krogstad. “As this year’s ICC takes place in Tokyo,
Japan, it provides a great opportunity for us to celebrate Medistims’ market
leading position with more than 80 % of the Coronary Artery Bypass market in
Japan, the highest share in the world outside our home-market Norway. It has
been a privilege for Medistim to work closely with outstanding Japanese surgeons
in our development of Medistim’s technology, providing the intraoperative
surgical guidance and quality control needed in these complex open-heart
procedures.”

“At Norway Health Tech, we have followed Medistim and the company's venture into
the Japanese market since 2018. We are proud and impressed by the solid
breakthrough the company has achieved, and the market leadership position the
company has managed to create within coronary bypass surgery. Norway has a goal
of increasing exports from mainland industries by 50 percent by 2030. In that
context, the health industry is crucial, because it is independent of the
economic cycle, and because Norway has world-class health technology that can
compete on the global market. Medistim is an excellent example of that, says CEO
of Norway Health Tech, Lena Nymo Helli.”

About Medistim:
Medistim was established in 1984 and has a track record of profitable growth
over the past 20 years. The company is a pioneer within its segment and
continues to invest in new product development. Medistim has wholly owned
subsidiaries with sales organizations in the USA, Germany, UK, Spain, Denmark,
and Norway, in addition to the about 50 distributors in Europe, Asia, Middle
East, Africa, Canada and South America. For more information, visit the
Medistim home page: www.medistim.com

For more information, contact:
President and CEO, Kari E. Krogstad, Medistim ASA
Tel: + 47 918 38 110
Email: kari.krogstad@medistim.com

CFO, Thomas Jakobsen, Medistim ASA
Tel: + 47 906 59 940
Email: thomas.jakobsen@medistim.com

More information:
Access the news on Oslo Bors NewsWeb site